Ph.D., Vice President, Research Strategy, Leukemia and Lymphoma Society
Dr. Amy Burd first began working with The Leukemia & Lymphoma Society in 2009 as senior director of LLS’s Therapy Acceleration Program, a strategic initiative through which LLS partners directly with biotechnology companies to help accelerate the development of promising therapies. In this role, she managed due diligence process for identifying strategic partnerships. In her current role, Dr. Burd provides strategic planning and oversight for mission special initiatives. She also leads LLS’s Beat AML initiative, a significant multi-institution collaboration to change the paradigm of treatment and improve outcomes for patients with acute myeloid leukemia (AML). Dr. Burd also leads other special research initiatives and collaborations. Prior to joining LLS, Dr. Burd was oncology portfolio manager at Bayer Pharmaceuticals and consultant to small biotechnology companies. Dr. Burd earned her doctorate in pharmacology from University of Minnesota-Twin Cities and her Bachelor of Science degree from Ohio Northern University.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Precision medicine holds tremendous promise for improved patient outcomes, but its full potential can only be realized as part of a comprehensive move toward precision health. This session will consider how to achieve a model in which care is centered around the individual and curated to fit their precise needs.